Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BCAL DiagnosticsASX:BDX Receivables Turnover is 0.41 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, BCAL Diagnostics ranks worse than 99.5% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BCAL Diagnostics's Revenue for the
six
months ended in Dec. 2025 was A$0.04 Mil. BCAL Diagnostics's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$0.11 Mil.
Hence, BCAL Diagnostics's Receivables Turnover for the
six
months ended in Dec. 2025 was 0.41.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BCAL Diagnostics Receivables Turnover Related Terms
BCAL Diagnostics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for BCAL Diagnostics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BDX vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, BCAL Diagnostics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BCAL Diagnostics Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BCAL Diagnostics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCAL Diagnostics (ASX:BDX) has a Receivables Turnover of 0.41 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BCAL Diagnostics and its competitors. According to the industry distribution chart, BCAL Diagnostics ranks #201 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 99.5%.
Is BCAL Diagnostics' Receivables Turnover too high?
BCAL Diagnostics' current Receivables Turnover is 0.41. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. BCAL Diagnostics' value of 0.41 is 92.4% below this industry median. Based on the distribution chart, BCAL Diagnostics ranks #201 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does BCAL Diagnostics' Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #201 out of 202 companies for Receivables Turnover. This places BCAL Diagnostics in the lower half of its industry. The industry median Receivables Turnover is 5.38. BCAL Diagnostics' value of 0.41 is 92.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BCAL Diagnostics's current Receivables Turnover of 0.41 is 92.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BCAL Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BCAL Diagnostics's current Receivables Turnover is 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Receivables Turnover of 0.41. The current Receivables Turnover is 0.41 and 92.4% below the Medical Diagnostics & Research industry median of 5.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Receivables Turnover is 0.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BDX has been successfully added to your 
